BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E, McKee CM, Moskowitz SM, Robertson S, Savage J, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Taylor-Cousar JL; VX16-445-001 Study Group. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018;379:1612-1620. [PMID: 30334692 DOI: 10.1056/nejmoa1807120] [Cited by in Crossref: 258] [Cited by in F6Publishing: 135] [Article Influence: 64.5] [Reference Citation Analysis]
Number Citing Articles
1 Dang Y, van Heusden C, Nickerson V, Chung F, Wang Y, Quinney NL, Gentzsch M, Randell SH, Moulton HM, Kole R, Ni A, Juliano RL, Kreda SM. Enhanced delivery of peptide-morpholino oligonucleotides with a small molecule to correct splicing defects in the lung. Nucleic Acids Res 2021;49:6100-13. [PMID: 34107015 DOI: 10.1093/nar/gkab488] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Manfredi C, Tindall JM, Hong JS, Sorscher EJ. Making precision medicine personal for cystic fibrosis. Science 2019;365:220-1. [PMID: 31320522 DOI: 10.1126/science.aaw0553] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
3 . Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis. Aust Prescr 2021;44:137-8. [PMID: 34421179 DOI: 10.18773/austprescr.2021.031] [Reference Citation Analysis]
4 Strub MD, McCray PB Jr. Transcriptomic and Proteostasis Networks of CFTR and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease. Genes (Basel) 2020;11:E546. [PMID: 32414011 DOI: 10.3390/genes11050546] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
5 Fukuda R, Okiyoneda T. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitylation as a Novel Pharmaceutical Target for Cystic Fibrosis. Pharmaceuticals (Basel) 2020;13:E75. [PMID: 32331485 DOI: 10.3390/ph13040075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Laselva O, McCormack J, Bartlett C, Ip W, Gunawardena TNA, Ouyang H, Eckford PDW, Gonska T, Moraes TJ, Bear CE. Preclinical Studies of a Rare CF-Causing Mutation in the Second Nucleotide Binding Domain (c.3700A>G) Show Robust Functional Rescue in Primary Nasal Cultures by Novel CFTR Modulators. J Pers Med 2020;10:E209. [PMID: 33167369 DOI: 10.3390/jpm10040209] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
7 Kunzelmann K, Ousingsawat J, Cabrita I, Doušová T, Bähr A, Janda M, Schreiber R, Benedetto R. TMEM16A in Cystic Fibrosis: Activating or Inhibiting? Front Pharmacol 2019;10:3. [PMID: 30761000 DOI: 10.3389/fphar.2019.00003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 11.7] [Reference Citation Analysis]
8 Armirotti A, Tomati V, Matthes E, Veit G, Cholon DM, Phuan PW, Braccia C, Guidone D, Gentzsch M, Lukacs GL, Verkman AS, Galietta LJV, Hanrahan JW, Pedemonte N. Bioactive Thymosin Alpha-1 Does Not Influence F508del-CFTR Maturation and Activity. Sci Rep 2019;9:10310. [PMID: 31311979 DOI: 10.1038/s41598-019-46639-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
9 Liu F, Zhang Z, Levit A, Levring J, Touhara KK, Shoichet BK, Chen J. Structural identification of a hotspot on CFTR for potentiation. Science 2019;364:1184-8. [PMID: 31221859 DOI: 10.1126/science.aaw7611] [Cited by in Crossref: 90] [Cited by in F6Publishing: 68] [Article Influence: 45.0] [Reference Citation Analysis]
10 Pascoe CD, Halayko AJ. Shot Down Inflamed: Airway Smooth Muscle Bronchodilator Insensitivity in Cystic Fibrosis. Am J Respir Cell Mol Biol 2019;60:379-81. [PMID: 30508386 DOI: 10.1165/rcmb.2018-0378ED] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
11 Bacon DR, Stapleton A, Goralski JL, Ebert CS Jr, Thorp BD, Nouraie M, Shaffer AD, Senior BA, Lee SE, Zemke AC, Kimple AJ. Olfaction before and after initiation of elexacaftor-tezacaftor-ivacaftor in a cystic fibrosis cohort. Int Forum Allergy Rhinol 2021. [PMID: 34709729 DOI: 10.1002/alr.22891] [Reference Citation Analysis]
12 Phuan PW, Haggie PM, Tan JA, Rivera AA, Finkbeiner WE, Nielson DW, Thomas MM, Janahi IA, Verkman AS. CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation. J Cyst Fibros 2021;20:452-9. [PMID: 32674984 DOI: 10.1016/j.jcf.2020.07.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
13 Verkman AS, Galietta LJV. Chloride transport modulators as drug candidates. Am J Physiol Cell Physiol 2021;321:C932-46. [PMID: 34644122 DOI: 10.1152/ajpcell.00334.2021] [Reference Citation Analysis]
14 Woodley FW, Gecili E, Szczesniak RD, Shrestha CL, Nemastil CJ, Kopp BT, Hayes D Jr. Sweat metabolomics before and after intravenous antibiotics for pulmonary exacerbation in people with cystic fibrosis. Respir Med 2021;191:106687. [PMID: 34864373 DOI: 10.1016/j.rmed.2021.106687] [Reference Citation Analysis]
15 Ortega VE, Li X, O'Neal WK, Lackey L, Ampleford E, Hawkins GA, Grayeski PJ, Laederach A, Barjaktarevic I, Barr RG, Cooper C, Couper D, Han MK, Kanner RE, Kleerup EC, Martinez FJ, Paine R 3rd, Peters SP, Pirozzi C, Rennard SI, Woodruff PG, Hoffman EA, Meyers DA, Bleecker ER; NHLBI Subpopulations and Intermediate Outcomes Measures in COPD Study (SPIROMICS). The Effects of Rare SERPINA1 Variants on Lung Function and Emphysema in SPIROMICS. Am J Respir Crit Care Med 2020;201:540-54. [PMID: 31661293 DOI: 10.1164/rccm.201904-0769OC] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
16 Suzuki S, Crane AM, Anirudhan V, Barillà C, Matthias N, Randell SH, Rab A, Sorscher EJ, Kerschner JL, Yin S, Harris A, Mendel M, Kim K, Zhang L, Conway A, Davis BR. Highly Efficient Gene Editing of Cystic Fibrosis Patient-Derived Airway Basal Cells Results in Functional CFTR Correction. Mol Ther 2020;28:1684-95. [PMID: 32402246 DOI: 10.1016/j.ymthe.2020.04.021] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
17 Marciniak SJ, Chambers JE, Ron D. Pharmacological targeting of endoplasmic reticulum stress in disease. Nat Rev Drug Discov 2021. [PMID: 34702991 DOI: 10.1038/s41573-021-00320-3] [Reference Citation Analysis]
18 Dougherty PG, Wellmerling JH, Koley A, Lukowski JK, Hummon AB, Cormet-Boyaka E, Pei D. Cyclic Peptidyl Inhibitors against CAL/CFTR Interaction for Treatment of Cystic Fibrosis. J Med Chem 2020;63:15773-84. [PMID: 33314931 DOI: 10.1021/acs.jmedchem.0c01528] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS; VX17-445-103 Trial Group. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 2019;394:1940-8. [PMID: 31679946 DOI: 10.1016/S0140-6736(19)32597-8] [Cited by in Crossref: 265] [Cited by in F6Publishing: 110] [Article Influence: 88.3] [Reference Citation Analysis]
20 Egan ME. Emerging technologies for cystic fibrosis transmembrane conductance regulator restoration in all people with CF. Pediatr Pulmonol 2021;56 Suppl 1:S32-9. [PMID: 32681713 DOI: 10.1002/ppul.24965] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Connett GJ. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy. Drug Des Devel Ther 2019;13:2405-12. [PMID: 31409974 DOI: 10.2147/DDDT.S153719] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
22 Arnaud F, Stremler-Le Bel N, Reynaud-Gaubert M, Mancini J, Gaubert JY, Gorincour G. Computed Tomographic Changes in Patients with Cystic Fibrosis Treated by Combination Therapy with Lumacaftor and Ivacaftor. J Clin Med 2021;10:1999. [PMID: 34066942 DOI: 10.3390/jcm10091999] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Sharma N, Cutting GR. The genetics and genomics of cystic fibrosis. J Cyst Fibros 2020;19 Suppl 1:S5-9. [PMID: 31879237 DOI: 10.1016/j.jcf.2019.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
24 Chen OG, Mather SE, Brommel CM, Hamilton BA, Ehler A, Villacreses R, Girgis RE, Abou Alaiwa M, Stoltz DA, Zabner J, Li X. Transduction of Pig Small Airway Epithelial Cells and Distal Lung Progenitor Cells by AAV4. Cells 2021;10:1014. [PMID: 33923029 DOI: 10.3390/cells10051014] [Reference Citation Analysis]
25 Rehman T, Thornell IM, Pezzulo AA, Thurman AL, Romano Ibarra GS, Karp PH, Tan P, Duffey ME, Welsh MJ. TNFα and IL-17 alkalinize airway surface liquid through CFTR and pendrin. Am J Physiol Cell Physiol 2020;319:C331-44. [PMID: 32432926 DOI: 10.1152/ajpcell.00112.2020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
26 Gao D, Morini E, Salani M, Krauson AJ, Chekuri A, Sharma N, Ragavendran A, Erdin S, Logan EM, Li W, Dakka A, Narasimhan J, Zhao X, Naryshkin N, Trotta CR, Effenberger KA, Woll MG, Gabbeta V, Karp G, Yu Y, Johnson G, Paquette WD, Cutting GR, Talkowski ME, Slaugenhaupt SA. A deep learning approach to identify gene targets of a therapeutic for human splicing disorders. Nat Commun 2021;12:3332. [PMID: 34099697 DOI: 10.1038/s41467-021-23663-2] [Reference Citation Analysis]
27 Krishnamurthy S, Traore S, Cooney AL, Brommel CM, Kulhankova K, Sinn PL, Newby GA, Liu DR, McCray PB. Functional correction of CFTR mutations in human airway epithelial cells using adenine base editors. Nucleic Acids Res 2021;49:10558-72. [PMID: 34520545 DOI: 10.1093/nar/gkab788] [Reference Citation Analysis]
28 Chen KG, Zhong P, Zheng W, Beekman JM. Pharmacological analysis of CFTR variants of cystic fibrosis using stem cell-derived organoids. Drug Discov Today 2019;24:2126-38. [PMID: 31173911 DOI: 10.1016/j.drudis.2019.05.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
29 Froux L, Coraux C, Sage E, Becq F. Short-term consequences of F508del-CFTR thermal instability on CFTR-dependent transepithelial currents in human airway epithelial cells. Sci Rep 2019;9:13729. [PMID: 31551433 DOI: 10.1038/s41598-019-50066-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
30 Veltman M, De Sanctis JB, Stolarczyk M, Klymiuk N, Bähr A, Brouwer RW, Oole E, Shah J, Ozdian T, Liao J, Martini C, Radzioch D, Hanrahan JW, Scholte BJ. CFTR Correctors and Antioxidants Partially Normalize Lipid Imbalance but not Abnormal Basal Inflammatory Cytokine Profile in CF Bronchial Epithelial Cells. Front Physiol 2021;12:619442. [PMID: 33613309 DOI: 10.3389/fphys.2021.619442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Mall MA. ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies. Eur Respir J 2020;56:2000946. [PMID: 32732328 DOI: 10.1183/13993003.00946-2020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
32 Neerincx AH, Whiteson K, Phan JL, Brinkman P, Abdel-Aziz MI, Weersink EJM, Altenburg J, Majoor CJ, Maitland-van der Zee AH, Bos LDJ. Lumacaftor/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients. ERJ Open Res 2021;7:00731-2020. [PMID: 33898610 DOI: 10.1183/23120541.00731-2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Valamparampil JJ, Gupte GL. Cystic fibrosis associated liver disease in children. World J Hepatol 2021; 13(11): 1727-1742 [PMID: 34904041 DOI: 10.4254/wjh.v13.i11.1727] [Reference Citation Analysis]
34 McKelvey MC, Weldon S, McAuley DF, Mall MA, Taggart CC. Targeting Proteases in Cystic Fibrosis Lung Disease. Paradigms, Progress, and Potential. Am J Respir Crit Care Med 2020;201:141-7. [PMID: 31626562 DOI: 10.1164/rccm.201906-1190PP] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
35 Capurro V, Tomati V, Sondo E, Renda M, Borrelli A, Pastorino C, Guidone D, Venturini A, Giraudo A, Mandrup Bertozzi S, Musante I, Bertozzi F, Bandiera T, Zara F, Galietta LJV, Pedemonte N. Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment. Int J Mol Sci 2021;22:5262. [PMID: 34067708 DOI: 10.3390/ijms22105262] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
36 Pratt J, Su W, Hayes D Jr, Clancy JP, Szczesniak RD. An Animated Functional Data Analysis Interface to Cluster Rapid Lung Function Decline and Enhance Center-Level Care in Cystic Fibrosis. J Healthc Eng 2021;2021:6671833. [PMID: 34094041 DOI: 10.1155/2021/6671833] [Reference Citation Analysis]
37 Yoshie S, Omori K, Hazama A. Airway regeneration using iPS cell-derived airway epithelial cells with Cl- channel function. Channels (Austin) 2019;13:227-34. [PMID: 31198082 DOI: 10.1080/19336950.2019.1628550] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 King NE, Suzuki S, Barillà C, Hawkins FJ, Randell SH, Reynolds SD, Stripp BR, Davis BR. Correction of Airway Stem Cells: Genome Editing Approaches for the Treatment of Cystic Fibrosis. Hum Gene Ther 2020;31:956-72. [PMID: 32741223 DOI: 10.1089/hum.2020.160] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Ghelani DP, Schneider-Futschik EK. Emerging Cystic Fibrosis Transmembrane Conductance Regulator Modulators as New Drugs for Cystic Fibrosis: A Portrait of in Vitro Pharmacology and Clinical Translation. ACS Pharmacol Transl Sci 2020;3:4-10. [PMID: 32259083 DOI: 10.1021/acsptsci.9b00060] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
40 Kim MD, Baumlin N, Yoshida M, Polineni D, Salathe SF, David JK, Peloquin CA, Wanner A, Dennis JS, Sailland J, Whitney P, Horrigan FT, Sabater JR, Abraham WM, Salathe M. Losartan Rescues Inflammation-related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis. Am J Respir Crit Care Med 2020;201:313-24. [PMID: 31613648 DOI: 10.1164/rccm.201905-0990OC] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
41 Guhr Lee TN, Cholon DM, Quinney NL, Gentzsch M, Esther CR Jr. Accumulation and persistence of ivacaftor in airway epithelia with prolonged treatment. J Cyst Fibros 2020;19:746-51. [PMID: 32536510 DOI: 10.1016/j.jcf.2020.04.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R; VX17-445-102 Study Group. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med 2019;381:1809-19. [PMID: 31697873 DOI: 10.1056/NEJMoa1908639] [Cited by in Crossref: 386] [Cited by in F6Publishing: 159] [Article Influence: 128.7] [Reference Citation Analysis]
43 McGarry ME, McColley SA. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. Pediatr Pulmonol 2021;56:1496-503. [PMID: 33470563 DOI: 10.1002/ppul.25285] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
44 Cruz DF, Mitash N, Farinha CM, Swiatecka-Urban A. TGF-β1 Augments the Apical Membrane Abundance of Lemur Tyrosine Kinase 2 to Inhibit CFTR-Mediated Chloride Transport in Human Bronchial Epithelia. Front Cell Dev Biol 2020;8:58. [PMID: 32117984 DOI: 10.3389/fcell.2020.00058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Griese M, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D, Quon BS, Ringshausen FC, Taylor-Cousar JL, Withers NJ, Moskowitz SM, Daines CL. Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial. Am J Respir Crit Care Med 2021;203:381-5. [PMID: 32969708 DOI: 10.1164/rccm.202008-3176LE] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 17.0] [Reference Citation Analysis]
46 Ramos KJ, Smith PJ, McKone EF, Pilewski JM, Lucy A, Hempstead SE, Tallarico E, Faro A, Rosenbluth DB, Gray AL, Dunitz JM; CF Lung Transplant Referral Guidelines Committee. Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines. J Cyst Fibros 2019;18:321-33. [PMID: 30926322 DOI: 10.1016/j.jcf.2019.03.002] [Cited by in Crossref: 59] [Cited by in F6Publishing: 40] [Article Influence: 19.7] [Reference Citation Analysis]
47 Scanio MJC, Searle XB, Liu B, Koenig JR, Altenbach R, Gfesser GA, Bogdan A, Greszler S, Zhao G, Singh A, Fan Y, Swensen AM, Vortherms T, Manelli A, Balut C, Jia Y, Gao W, Yong H, Schrimpf M, Tse C, Kym P, Wang X. Discovery of ABBV/GLPG-3221, a Potent Corrector of CFTR for the Treatment of Cystic Fibrosis. ACS Med Chem Lett 2019;10:1543-8. [PMID: 31749908 DOI: 10.1021/acsmedchemlett.9b00377] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
48 Rehman T, Karp PH, Tan P, Goodell BJ, Pezzulo AA, Thurman AL, Thornell IM, Durfey SL, Duffey ME, Stoltz DA, McKone EF, Singh PK, Welsh MJ. Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators. J Clin Invest 2021;131:150398. [PMID: 34166230 DOI: 10.1172/JCI150398] [Reference Citation Analysis]
49 Meoli A, Fainardi V, Deolmi M, Chiopris G, Marinelli F, Caminiti C, Esposito S, Pisi G. State of the Art on Approved Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators and Triple-Combination Therapy. Pharmaceuticals (Basel) 2021;14:928. [PMID: 34577628 DOI: 10.3390/ph14090928] [Reference Citation Analysis]
50 Spanò V, Barreca M, Cilibrasi V, Genovese M, Renda M, Montalbano A, Galietta LJV, Barraja P. Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein. Molecules 2021;26:1275. [PMID: 33652850 DOI: 10.3390/molecules26051275] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
51 Sepahzad A, Morris-Rosendahl DJ, Davies JC. Cystic Fibrosis Lung Disease Modifiers and Their Relevance in the New Era of Precision Medicine. Genes (Basel) 2021;12:562. [PMID: 33924524 DOI: 10.3390/genes12040562] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Dhooghe B, Bouzin C, Mottais A, Hermans E, Delion M, Panin N, Noel S, Leal T. Vardenafil increases intracellular accumulation of the most prevalent mutant cystic fibrosis transmembrane conductance regulator (CTFR) in human bronchial epithelial cells. Biol Open 2020;9:bio053116. [PMID: 32747447 DOI: 10.1242/bio.053116] [Reference Citation Analysis]
53 Wang C, Zhao P, Sun S, Teckman J, Balch WE. Leveraging Population Genomics for Individualized Correction of the Hallmarks of Alpha-1 Antitrypsin Deficiency. Chronic Obstr Pulm Dis 2020;7:224-46. [PMID: 32726074 DOI: 10.15326/jcopdf.7.3.2019.0167] [Reference Citation Analysis]
54 Weinberger M, Hurvitz M. Diagnosis and management of chronic cough: similarities and differences between children and adults. F1000Res 2020;9:F1000 Faculty Rev-757. [PMID: 32765833 DOI: 10.12688/f1000research.25468.1] [Reference Citation Analysis]
55 Pedemonte N, Bertozzi F, Caci E, Sorana F, Di Fruscia P, Tomati V, Ferrera L, Rodríguez-Gimeno A, Berti F, Pesce E, Sondo E, Gianotti A, Scudieri P, Bandiera T, Galietta LJV. Discovery of a picomolar potency pharmacological corrector of the mutant CFTR chloride channel. Sci Adv 2020;6:eaay9669. [PMID: 32128418 DOI: 10.1126/sciadv.aay9669] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
56 Addy C, Schock BC. Putting CHIP(s) on the Table: Introducing Nitrosothiols into the Arena of CFTR Modulation. Am J Respir Cell Mol Biol 2019;61:673-5. [PMID: 31600091 DOI: 10.1165/rcmb.2019-0045ED] [Reference Citation Analysis]
57 Yanda MK, Cha B, Cebotaru CV, Cebotaru L. Pharmacological reversal of renal cysts from secretion to absorption suggests a potential therapeutic strategy for managing autosomal dominant polycystic kidney disease. J Biol Chem 2019;294:17090-104. [PMID: 31570523 DOI: 10.1074/jbc.RA119.010320] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
58 Mall MA, Mayer-Hamblett N, Rowe SM. Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications. Am J Respir Crit Care Med 2020;201:1193-208. [PMID: 31860331 DOI: 10.1164/rccm.201910-1943SO] [Cited by in Crossref: 34] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
59 Chen Q, Shen Y, Zheng J. A review of cystic fibrosis: Basic and clinical aspects. Animal Model Exp Med 2021;4:220-32. [PMID: 34557648 DOI: 10.1002/ame2.12180] [Reference Citation Analysis]
60 Clunes LA, McMillan-Castanares N, Mehta N, Mesadieu A, Rodriguez J, Maj M, Clunes MT. Epithelial vectorial ion transport in cystic fibrosis: Dysfunction, measurement, and pharmacotherapy to target the primary deficit. SAGE Open Med 2020;8:2050312120933807. [PMID: 32637102 DOI: 10.1177/2050312120933807] [Reference Citation Analysis]
61 Lopes-Pacheco M. CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. Front Pharmacol 2019;10:1662. [PMID: 32153386 DOI: 10.3389/fphar.2019.01662] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 31.5] [Reference Citation Analysis]
62 Nguyen JP, Bianca M, Huff RD, Tiessen N, Inman MD, Hirota JA. Modulation of cAMP metabolism for CFTR potentiation in human airway epithelial cells. Sci Rep 2021;11:904. [PMID: 33441643 DOI: 10.1038/s41598-020-79555-w] [Reference Citation Analysis]
63 Homolya L. Medically Important Alterations in Transport Function and Trafficking of ABCG2. Int J Mol Sci 2021;22:2786. [PMID: 33801813 DOI: 10.3390/ijms22062786] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
64 Smirnikhina SA, Kondrateva EV, Adilgereeva EP, Anuchina AA, Zaynitdinova MI, Slesarenko YS, Ershova AS, Ustinov KD, Yasinovsky MI, Amelina EL, Voronina ES, Yakushina VD, Tabakov VY, Lavrov AV. P.F508del editing in cells from cystic fibrosis patients. PLoS One 2020;15:e0242094. [PMID: 33175893 DOI: 10.1371/journal.pone.0242094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Hodos RA, Strub MD, Ramachandran S, Meleshkevitch EA, Boudko DY, Bridges RJ, Dudley JT, McCray PB Jr. Integrative chemogenomic analysis identifies small molecules that partially rescue ΔF508-CFTR for cystic fibrosis. CPT Pharmacometrics Syst Pharmacol 2021;10:500-10. [PMID: 33934548 DOI: 10.1002/psp4.12626] [Reference Citation Analysis]
66 Gramegna A, Contarini M, Aliberti S, Casciaro R, Blasi F, Castellani C. From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis. Int J Mol Sci 2020;21:E5882. [PMID: 32824306 DOI: 10.3390/ijms21165882] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
67 Gochuico BR, Ziegler SG, Ten NS, Balanda NJ, Mason CE, Zumbo P, Evans CA, Van Waes C, Gahl WA, Malicdan MCV. A comprehensive, multidisciplinary, precision medicine approach to discover effective therapy for an undiagnosed, progressive, fibroinflammatory disease. Transl Res 2020;215:31-40. [PMID: 31520587 DOI: 10.1016/j.trsl.2019.08.008] [Reference Citation Analysis]
68 Nick HJ, Zeitlin PL, Yadav S, Bratcher PE. Measurements of spontaneous CFTR-mediated ion transport without acute channel activation in airway epithelial cultures after modulator exposure. Sci Rep 2021;11:22616. [PMID: 34799640 DOI: 10.1038/s41598-021-02044-1] [Reference Citation Analysis]
69 Bieniek JM, Lapin CD, Jarvi KA. Genetics of CFTR and male infertility. Transl Androl Urol 2021;10:1391-400. [PMID: 33850775 DOI: 10.21037/tau.2020.04.05] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
70 Graeber SY, Vitzthum C, Mall MA. Potential of Intestinal Current Measurement for Personalized Treatment of Patients with Cystic Fibrosis. J Pers Med 2021;11:384. [PMID: 34066648 DOI: 10.3390/jpm11050384] [Reference Citation Analysis]
71 Sergeev V, Chou FY, Lam GY, Hamilton CM, Wilcox PG, Quon BS. The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis. Ann Am Thorac Soc 2020;17:147-54. [PMID: 31661636 DOI: 10.1513/AnnalsATS.201909-671CME] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 24.0] [Reference Citation Analysis]
72 Keegan DE, Brewington JJ. Nasal Epithelial Cell-Based Models for Individualized Study in Cystic Fibrosis. Int J Mol Sci 2021;22:4448. [PMID: 33923202 DOI: 10.3390/ijms22094448] [Reference Citation Analysis]
73 Keown K, Brown R, Doherty DF, Houston C, McKelvey MC, Creane S, Linden D, McAuley DF, Kidney JC, Weldon S, Downey DG, Taggart CC. Airway Inflammation and Host Responses in the Era of CFTR Modulators. Int J Mol Sci 2020;21:E6379. [PMID: 32887484 DOI: 10.3390/ijms21176379] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
74 Staufer K. Current Treatment Options for Cystic Fibrosis-Related Liver Disease. Int J Mol Sci 2020;21:E8586. [PMID: 33202578 DOI: 10.3390/ijms21228586] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
75 Laselva O, Guerra L, Castellani S, Favia M, Di Gioia S, Conese M. Small-molecule drugs for cystic fibrosis: Where are we now? Pulm Pharmacol Ther 2021;:102098. [PMID: 34793977 DOI: 10.1016/j.pupt.2021.102098] [Reference Citation Analysis]
76 Beumer W, Swildens J, Leal T, Noel S, Anthonijsz H, van der Horst G, Kuiperij-Boersma H, Potman M, van Putten C, Biasutto P, Platenburg G, de Jonge H, Henig N, Ritsema T. Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosis. PLoS One 2019;14:e0219182. [PMID: 31251792 DOI: 10.1371/journal.pone.0219182] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
77 Gifford AH, Mayer-Hamblett N, Pearson K, Nichols DP. Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy. J Cyst Fibros 2020;19:762-7. [PMID: 31761739 DOI: 10.1016/j.jcf.2019.11.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
78 Scudieri P, Musante I, Venturini A, Guidone D, Genovese M, Cresta F, Caci E, Palleschi A, Poeta M, Santamaria F, Ciciriello F, Lucidi V, Galietta LJV. Ionocytes and CFTR Chloride Channel Expression in Normal and Cystic Fibrosis Nasal and Bronchial Epithelial Cells. Cells 2020;9:E2090. [PMID: 32933106 DOI: 10.3390/cells9092090] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
79 Berical A, Lee RE, Randell SH, Hawkins F. Challenges Facing Airway Epithelial Cell-Based Therapy for Cystic Fibrosis. Front Pharmacol 2019;10:74. [PMID: 30800069 DOI: 10.3389/fphar.2019.00074] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
80 Cottrill KA, Peterson RJ, Lewallen CF, Koval M, Bridges RJ, McCarty NA. Sphingomyelinase decreases transepithelial anion secretion in airway epithelial cells in part by inhibiting CFTR-mediated apical conductance. Physiol Rep 2021;9:e14928. [PMID: 34382377 DOI: 10.14814/phy2.14928] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
81 Künzi L, Easter M, Hirsch MJ, Krick S. Cystic Fibrosis Lung Disease in the Aging Population. Front Pharmacol 2021;12:601438. [PMID: 33935699 DOI: 10.3389/fphar.2021.601438] [Reference Citation Analysis]
82 Pecoraro M, Franceschelli S, Pascale M. Lumacaftor and Matrine: Possible Therapeutic Combination to Counteract the Inflammatory Process in Cystic Fibrosis. Biomolecules 2021;11:422. [PMID: 33805605 DOI: 10.3390/biom11030422] [Reference Citation Analysis]
83 Sharma J, Keeling KM, Rowe SM. Pharmacological approaches for targeting cystic fibrosis nonsense mutations. Eur J Med Chem 2020;200:112436. [PMID: 32512483 DOI: 10.1016/j.ejmech.2020.112436] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
84 Mutyam V, Sharma J, Li Y, Peng N, Chen J, Tang LP, Falk Libby E, Singh AK, Conrath K, Rowe SM. Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations. Am J Respir Cell Mol Biol 2021;64:604-16. [PMID: 33616476 DOI: 10.1165/rcmb.2019-0291OC] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
85 Ribeiro CMP, Gentzsch M. Impact of Airway Inflammation on the Efficacy of CFTR Modulators. Cells 2021;10:3260. [PMID: 34831482 DOI: 10.3390/cells10113260] [Reference Citation Analysis]
86 Erwood S, Laselva O, Bily TMI, Brewer RA, Rutherford AH, Bear CE, Ivakine EA. Allele-Specific Prevention of Nonsense-Mediated Decay in Cystic Fibrosis Using Homology-Independent Genome Editing. Mol Ther Methods Clin Dev 2020;17:1118-28. [PMID: 32490033 DOI: 10.1016/j.omtm.2020.05.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
87 Athwal VS, Scott JA, Fitzpatrick E, Rowland M. Emerging clinical perspectives in cystic fibrosis liver disease. Curr Opin Pulm Med 2021;27:593-9. [PMID: 34482340 DOI: 10.1097/MCP.0000000000000824] [Reference Citation Analysis]
88 Veit G, Roldan A, Hancock MA, Da Fonte DF, Xu H, Hussein M, Frenkiel S, Matouk E, Velkov T, Lukacs GL. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination. JCI Insight 2020;5:139983. [PMID: 32853178 DOI: 10.1172/jci.insight.139983] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 14.5] [Reference Citation Analysis]
89 Reyes-Ortega F, Qiu F, Schneider-Futschik EK. Multiple Reaction Monitoring Mass Spectrometry for the Drug Monitoring of Ivacaftor, Tezacaftor, and Elexacaftor Treatment Response in Cystic Fibrosis: A High-Throughput Method. ACS Pharmacol Transl Sci 2020;3:987-96. [PMID: 33073196 DOI: 10.1021/acsptsci.0c00103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
90 Bergeron C, Cantin AM. New Therapies to Correct the Cystic Fibrosis Basic Defect. Int J Mol Sci 2021;22:6193. [PMID: 34201249 DOI: 10.3390/ijms22126193] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
91 Li H, Valkenier H, Thorne AG, Dias CM, Cooper JA, Kieffer M, Busschaert N, Gale PA, Sheppard DN, Davis AP. Anion carriers as potential treatments for cystic fibrosis: transport in cystic fibrosis cells, and additivity to channel-targeting drugs. Chem Sci 2019;10:9663-72. [PMID: 32055336 DOI: 10.1039/c9sc04242c] [Cited by in Crossref: 28] [Cited by in F6Publishing: 3] [Article Influence: 9.3] [Reference Citation Analysis]
92 Chorghade RS, Kim BR, Launspach JL, Karp PH, Welsh MJ, Burke MD. Amphotericin B induces epithelial voltage responses in people with cystic fibrosis. J Cyst Fibros 2021;20:540-50. [PMID: 33309058 DOI: 10.1016/j.jcf.2020.11.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
93 Sabbadini R, Pesce E, Parodi A, Mustorgi E, Bruzzone S, Pedemonte N, Casale M, Millo E, Cichero E. Probing Allosteric Hsp70 Inhibitors by Molecular Modelling Studies to Expedite the Development of Novel Combined F508del CFTR Modulators. Pharmaceuticals (Basel) 2021;14:1296. [PMID: 34959696 DOI: 10.3390/ph14121296] [Reference Citation Analysis]
94 Benden C, Schwarz C. CFTR Modulator Therapy and Its Impact on Lung Transplantation in Cystic Fibrosis. Pulm Ther 2021;7:377-93. [PMID: 34406641 DOI: 10.1007/s41030-021-00170-9] [Reference Citation Analysis]
95 Aridgides D, Dessaint J, Atkins G, Carroll J, Ashare A. Safety of research bronchoscopy with BAL in stable adult patients with cystic fibrosis. PLoS One 2021;16:e0245696. [PMID: 33481845 DOI: 10.1371/journal.pone.0245696] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
96 Aridgides DS, Mellinger DL, Armstrong DA, Hazlett HF, Dessaint JA, Hampton TH, Atkins GT, Carroll JL, Ashare A. Functional and metabolic impairment in cigarette smoke-exposed macrophages is tied to oxidative stress. Sci Rep 2019;9:9624. [PMID: 31270372 DOI: 10.1038/s41598-019-46045-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
97 Ramsey BW, Downey GP, Goss CH. Update in Cystic Fibrosis 2018. Am J Respir Crit Care Med 2019;199:1188-94. [PMID: 30917288 DOI: 10.1164/rccm.201902-0310UP] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
98 Estabrooks S, Brodsky JL. Regulation of CFTR Biogenesis by the Proteostatic Network and Pharmacological Modulators. Int J Mol Sci 2020;21:E452. [PMID: 31936842 DOI: 10.3390/ijms21020452] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
99 Yiallouros PK, Matthaiou AΜ, Anagnostopoulou P, Kouis P, Libik M, Adamidi T, Eleftheriou A, Demetriou A, Ioannou P, Tanteles GA, Costi C, Fanis P, Macek M, Neocleous V, Phylactou LA. Demographic characteristics, clinical and laboratory features, and the distribution of pathogenic variants in the CFTR gene in the Cypriot cystic fibrosis (CF) population demonstrate the utility of a national CF patient registry. Orphanet J Rare Dis 2021;16:409. [PMID: 34600583 DOI: 10.1186/s13023-021-02049-z] [Reference Citation Analysis]
100 Shei RJ, Mackintosh KA, Peabody Lever JE, McNarry MA, Krick S. Exercise Physiology Across the Lifespan in Cystic Fibrosis. Front Physiol 2019;10:1382. [PMID: 31780953 DOI: 10.3389/fphys.2019.01382] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
101 He L, Kennedy AS, Houck S, Aleksandrov A, Quinney NL, Cyr-Scully A, Cholon DM, Gentzsch M, Randell SH, Ren HY, Cyr DM. DNAJB12 and Hsp70 triage arrested intermediates of N1303K-CFTR for endoplasmic reticulum-associated autophagy. Mol Biol Cell 2021;32:538-53. [PMID: 33534640 DOI: 10.1091/mbc.E20-11-0688] [Reference Citation Analysis]
102 Bartley BL, Schwartz CE, Stark RB, Georgiopoulos AM, Friedman D, Richards CJ, Dorkin HL, Kinane TB, Neuringer IP, Yonker LM. Lung transplant referral practice patterns: a survey of cystic fibrosis physicians and general pulmonologists. BMC Pulm Med 2020;20:58. [PMID: 32131782 DOI: 10.1186/s12890-020-1067-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
103 Bijvelds MJC, Roos FJM, Meijsen KF, Roest HP, Verstegen MMA, Janssens HM, van der Laan LJW, de Jonge HR. Rescue of chloride and bicarbonate transport by elexacaftor-ivacaftor-tezacaftor in organoid-derived CF intestinal and cholangiocyte monolayers. J Cyst Fibros 2021:S1569-1993(21)02165-2. [PMID: 34922851 DOI: 10.1016/j.jcf.2021.12.006] [Reference Citation Analysis]
104 Cabrini G. Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure. Mol Diagn Ther 2019;23:263-79. [PMID: 30478715 DOI: 10.1007/s40291-018-0372-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
105 Lee SE, Farzal Z, Daniels MLA, Thorp BD, Zanation AM, Senior BA, Ebert CS Jr, Kimple AJ. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist. Am J Rhinol Allergy 2020;34:573-80. [PMID: 32168995 DOI: 10.1177/1945892420912368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
106 Shaughnessy CA, Zeitlin PL, Bratcher PE. Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment. Sci Rep 2021;11:19810. [PMID: 34615919 DOI: 10.1038/s41598-021-99184-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
107 Centko RM, Carlile GW, Barne I, Patrick BO, Blagojevic P, Thomas DY, Andersen RJ. Combination of Selective PARP3 and PARP16 Inhibitory Analogues of Latonduine A Corrects F508del-CFTR Trafficking. ACS Omega 2020;5:25593-604. [PMID: 33073085 DOI: 10.1021/acsomega.0c02467] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
108 Bratcher PE, Yadav S, Shaughnessy CA, Thornell IM, Zeitlin PL. Effect of apical chloride concentration on the measurement of responses to CFTR modulation in airway epithelia cultured from nasal brushings. Physiol Rep 2020;8:e14603. [PMID: 33038073 DOI: 10.14814/phy2.14603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
109 Hodges CA, Conlon RA. Delivering on the promise of gene editing for cystic fibrosis. Genes Dis 2019;6:97-108. [PMID: 31193992 DOI: 10.1016/j.gendis.2018.11.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
110 Shrestha CL, Zhang S, Wisniewski B, Häfner S, Elie J, Meijer L, Kopp BT. (R)-Roscovitine and CFTR modulators enhance killing of multi-drug resistant Burkholderia cenocepacia by cystic fibrosis macrophages. Sci Rep 2020;10:21700. [PMID: 33303916 DOI: 10.1038/s41598-020-78817-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
111 Wang C, Scott SM, Sun S, Zhao P, Hutt DM, Shao H, Gestwicki JE, Balch WE. Individualized management of genetic diversity in Niemann-Pick C1 through modulation of the Hsp70 chaperone system. Hum Mol Genet 2020;29:1-19. [PMID: 31509197 DOI: 10.1093/hmg/ddz215] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
112 Balfour-Lynn IM. Clinical papers of the year 2018 - Cystic fibrosis. Paediatr Respir Rev 2020;33:58-61. [PMID: 31053358 DOI: 10.1016/j.prrv.2019.03.008] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
113 Stashower J, Carr P, Miller V, Zlotoff B. Novel reaction to new cystic fibrosis medication Trikafta. Clin Case Rep 2021;9:e04116. [PMID: 34026156 DOI: 10.1002/ccr3.4116] [Reference Citation Analysis]
114 Laselva O, Ardelean MC, Bear CE. Phenotyping Rare CFTR Mutations Reveal Functional Expression Defects Restored by TRIKAFTATM. J Pers Med 2021;11:301. [PMID: 33920764 DOI: 10.3390/jpm11040301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
115 Sharma J, Du M, Wong E, Mutyam V, Li Y, Chen J, Wangen J, Thrasher K, Fu L, Peng N, Tang L, Liu K, Mathew B, Bostwick RJ, Augelli-Szafran CE, Bihler H, Liang F, Mahiou J, Saltz J, Rab A, Hong J, Sorscher EJ, Mendenhall EM, Coppola CJ, Keeling KM, Green R, Mense M, Suto MJ, Rowe SM, Bedwell DM. A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion. Nat Commun 2021;12:4358. [PMID: 34272367 DOI: 10.1038/s41467-021-24575-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Krajewska J, Zub K, Słowikowski A, Zatoński T. Chronic rhinosinusitis in cystic fibrosis: a review of therapeutic options. Eur Arch Otorhinolaryngol 2021. [PMID: 34296343 DOI: 10.1007/s00405-021-06875-6] [Reference Citation Analysis]
117 Bitam S, Elbahnsi A, Creste G, Pranke I, Chevalier B, Berhal F, Hoffmann B, Servel N, Baatalah N, Tondelier D, Hatton A, Moquereau C, Faria Da Cunha M, Pastor A, Lepissier A, Hinzpeter A, Mornon JP, Prestat G, Edelman A, Callebaut I, Gravier-Pelletier C, Sermet-Gaudelus I. New insights into structure and function of bis-phosphinic acid derivatives and implications for CFTR modulation. Sci Rep 2021;11:6842. [PMID: 33767236 DOI: 10.1038/s41598-021-83240-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
118 Deignan JL, Astbury C, Cutting GR, Del Gaudio D, Gregg AR, Grody WW, Monaghan KG, Richards S; ACMG Laboratory Quality Assurance Committee. CFTR variant testing: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2020;22:1288-95. [PMID: 32404922 DOI: 10.1038/s41436-020-0822-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
119 Lopes-Pacheco M, Pedemonte N, Kicic A. Editorial: Emerging Therapeutic Approaches for Cystic Fibrosis. Front Pharmacol 2019;10:1440. [PMID: 31849681 DOI: 10.3389/fphar.2019.01440] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
120 Pranke I, Golec A, Hinzpeter A, Edelman A, Sermet-Gaudelus I. Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine. Front Pharmacol. 2019;10:121. [PMID: 30873022 DOI: 10.3389/fphar.2019.00121] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 13.3] [Reference Citation Analysis]
121 Phuan PW, Tan JA, Rivera AA, Zlock L, Nielson DW, Finkbeiner WE, Haggie PM, Verkman AS. Nanomolar-potency 'co-potentiator' therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants. Sci Rep 2019;9:17640. [PMID: 31776420 DOI: 10.1038/s41598-019-54158-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
122 Goss CH. Acute Pulmonary Exacerbations in Cystic Fibrosis. Semin Respir Crit Care Med 2019;40:792-803. [PMID: 31659730 DOI: 10.1055/s-0039-1697975] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
123 Liessi N, Pesce E, Braccia C, Bertozzi SM, Giraudo A, Bandiera T, Pedemonte N, Armirotti A. Distinctive lipid signatures of bronchial epithelial cells associated with cystic fibrosis drugs, including Trikafta. JCI Insight 2020;5:138722. [PMID: 32673287 DOI: 10.1172/jci.insight.138722] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
124 Ensinck M, Mottais A, Detry C, Leal T, Carlon MS. On the Corner of Models and Cure: Gene Editing in Cystic Fibrosis. Front Pharmacol 2021;12:662110. [PMID: 33986686 DOI: 10.3389/fphar.2021.662110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Mitash N, Mu F, Donovan JE, Myerburg MM, Ranganathan S, Greene CM, Swiatecka-Urban A. Transforming Growth Factor-β1 Selectively Recruits microRNAs to the RNA-Induced Silencing Complex and Degrades CFTR mRNA under Permissive Conditions in Human Bronchial Epithelial Cells. Int J Mol Sci 2019;20:E4933. [PMID: 31590401 DOI: 10.3390/ijms20194933] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
126 Cao H, Duan R, Hu J. Overcoming Immunological Challenges to Helper-Dependent Adenoviral Vector-Mediated Long-Term CFTR Expression in Mouse Airways. Genes (Basel) 2020;11:E565. [PMID: 32443586 DOI: 10.3390/genes11050565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
127 Mancini G, Loberto N, Olioso D, Dechecchi MC, Cabrini G, Mauri L, Bassi R, Schiumarini D, Chiricozzi E, Lippi G, Pesce E, Sonnino S, Pedemonte N, Tamanini A, Aureli M. GM1 as Adjuvant of Innovative Therapies for Cystic Fibrosis Disease. Int J Mol Sci 2020;21:E4486. [PMID: 32599772 DOI: 10.3390/ijms21124486] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
128 Scotet V, L'Hostis C, Férec C. The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery. Genes (Basel) 2020;11:E589. [PMID: 32466381 DOI: 10.3390/genes11060589] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
129 Yanda MK, Tomar V, Cebotaru C, Guggino W, Cebotaru L. Short-term steroid treatment of Rhesus macaque increases transduction. Hum Gene Ther 2021. [PMID: 34806411 DOI: 10.1089/hum.2021.239] [Reference Citation Analysis]
130 Moheet A, Beisang D, Zhang L, Sagel SD, VanDalfsen JM, Heltshe SL, Frederick C, Mann M, Antos N, Billings J, Rowe SM, Moran A; PROSPECT Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients. J Cyst Fibros 2021;20:333-8. [PMID: 32917547 DOI: 10.1016/j.jcf.2020.09.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
131 Leven C, Schutz S, Audrezet MP, Nowak E, Meijer L, Montier T. Non-Linear Pharmacokinetics of Oral Roscovitine (Seliciclib) in Cystic Fibrosis Patients Chronically Infected with Pseudomonas aeruginosa: A Study on Population Pharmacokinetics with Monte Carlo Simulations. Pharmaceutics 2020;12:E1087. [PMID: 33198319 DOI: 10.3390/pharmaceutics12111087] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
132 Laselva O, Bartlett C, Gunawardena TNA, Ouyang H, Eckford PDW, Moraes TJ, Bear CE, Gonska T. Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator. Eur Respir J 2021;57:2002774. [PMID: 33303536 DOI: 10.1183/13993003.02774-2020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
133 Quaresma MC, Pankonien I, Clarke LA, Sousa LS, Silva IAL, Railean V, Doušová T, Fuxe J, Amaral MD. Mutant CFTR Drives TWIST1 mediated epithelial-mesenchymal transition. Cell Death Dis 2020;11:920. [PMID: 33106471 DOI: 10.1038/s41419-020-03119-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
134 Mitri C, Xu Z, Bardin P, Corvol H, Touqui L, Tabary O. Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies. Front Pharmacol 2020;11:1096. [PMID: 32848733 DOI: 10.3389/fphar.2020.01096] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
135 Ferrera L, Cappiello F, Loffredo MR, Puglisi E, Casciaro B, Botta B, Galietta LJV, Mori M, Mangoni ML. Esc peptides as novel potentiators of defective cystic fibrosis transmembrane conductance regulator: an unprecedented property of antimicrobial peptides. Cell Mol Life Sci 2021. [PMID: 34971429 DOI: 10.1007/s00018-021-04030-2] [Reference Citation Analysis]
136 Brandas C, Ludovico A, Parodi A, Moran O, Millo E, Cichero E, Baroni D. NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis. Biomolecules 2021;11:1417. [PMID: 34680050 DOI: 10.3390/biom11101417] [Reference Citation Analysis]
137 Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev 2020;12:CD010966. [PMID: 33331662 DOI: 10.1002/14651858.CD010966.pub3] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
138 Ghigo A, Prono G, Riccardi E, De Rose V. Dysfunctional Inflammation in Cystic Fibrosis Airways: From Mechanisms to Novel Therapeutic Approaches. Int J Mol Sci 2021;22:1952. [PMID: 33669352 DOI: 10.3390/ijms22041952] [Reference Citation Analysis]
139 McCague AF, Raraigh KS, Pellicore MJ, Davis-Marcisak EF, Evans TA, Han ST, Lu Z, Joynt AT, Sharma N, Castellani C, Collaco JM, Corey M, Lewis MH, Penland CM, Rommens JM, Stephenson AL, Sosnay PR, Cutting GR. Correlating Cystic Fibrosis Transmembrane Conductance Regulator Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis. Am J Respir Crit Care Med 2019;199:1116-26. [PMID: 30888834 DOI: 10.1164/rccm.201901-0145OC] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 15.0] [Reference Citation Analysis]
140 Martiniano SL, Daines CL, Dellon EP, Esther CR, Muhlebach MS, Ong T, Rabinowitz EC, Toprak D, Zemanick ET. Highlights from the 2018 North American cystic fibrosis conference. Pediatr Pulmonol 2019;54:941-8. [DOI: 10.1002/ppul.24356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
141 Carnovale V, Iacotucci P, Terlizzi V, Colangelo C, Medio P, Ferrillo L, De Gregorio F, Francalanci M, Taccetti G, Buonaurio S, d'Ippolito M, Marsicovetere G, D'Andria M, Ferrara N, Salvatore D. Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype. Respir Med 2021;189:106646. [PMID: 34673344 DOI: 10.1016/j.rmed.2021.106646] [Reference Citation Analysis]
142 Tambuyzer E, Vandendriessche B, Austin CP, Brooks PJ, Larsson K, Miller Needleman KI, Valentine J, Davies K, Groft SC, Preti R, Oprea TI, Prunotto M. Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. Nat Rev Drug Discov 2020;19:93-111. [PMID: 31836861 DOI: 10.1038/s41573-019-0049-9] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 15.3] [Reference Citation Analysis]
143 Ogawa M, Jiang JX, Xia S, Yang D, Ding A, Laselva O, Hernandez M, Cui C, Higuchi Y, Suemizu H, Dorrell C, Grompe M, Bear CE, Ogawa S. Generation of functional ciliated cholangiocytes from human pluripotent stem cells. Nat Commun 2021;12:6504. [PMID: 34764255 DOI: 10.1038/s41467-021-26764-0] [Reference Citation Analysis]
144 Anderson JD, Liu Z, Odom LV, Kersh L, Guimbellot JS. CFTR function and clinical response to modulators parallel nasal epithelial organoid swelling. Am J Physiol Lung Cell Mol Physiol 2021;321:L119-29. [PMID: 34009038 DOI: 10.1152/ajplung.00639.2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
145 Kutney K, Donnola SB, Flask CA, Gubitosi-Klug R, O’Riordan M, McBennett K, Sferra TJ, Kaminski B. Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients. World J Hepatol 2019; 11(12): 761-772 [PMID: 31966908 DOI: 10.4254/wjh.v11.i12.761] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
146 Vandebrouck C, Ferreira T. Glued in lipids: Lipointoxication in cystic fibrosis. EBioMedicine 2020;61:103038. [PMID: 33038767 DOI: 10.1016/j.ebiom.2020.103038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
147 Girón Moreno RM, García-Clemente M, Diab-Cáceres L, Martínez-Vergara A, Martínez-García MÁ, Gómez-Punter RM. Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review. Antibiotics (Basel) 2021;10:486. [PMID: 33922413 DOI: 10.3390/antibiotics10050486] [Reference Citation Analysis]
148 Barbieri A, Thonghin N, Shafi T, Prince SM, Collins RF, Ford RC. Structure of ABCB1/P-Glycoprotein in the Presence of the CFTR Potentiator Ivacaftor. Membranes (Basel) 2021;11:923. [PMID: 34940424 DOI: 10.3390/membranes11120923] [Reference Citation Analysis]
149 Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, Plant BJ, Prais D, Ramsey BW, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM; VX16-659-101 Study Group. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018;379:1599-1611. [PMID: 30334693 DOI: 10.1056/nejmoa1807119] [Cited by in Crossref: 185] [Cited by in F6Publishing: 81] [Article Influence: 46.3] [Reference Citation Analysis]
150 Chan EG, Hyzny EJ, Ryan JP, Morrell MR, Pilewski J, Sanchez PG. Outcomes following lung re-transplantation in patients with cystic fibrosis. J Cyst Fibros 2021:S1569-1993(21)02162-7. [PMID: 34949557 DOI: 10.1016/j.jcf.2021.12.002] [Reference Citation Analysis]
151 Gentzsch M, Cholon DM, Quinney NL, Martino MEB, Minges JT, Boyles SE, Guhr Lee TN, Esther CR Jr, Ribeiro CMP. Airway Epithelial Inflammation In Vitro Augments the Rescue of Mutant CFTR by Current CFTR Modulator Therapies. Front Pharmacol 2021;12:628722. [PMID: 33859562 DOI: 10.3389/fphar.2021.628722] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Mithal A, Capilla A, Heinze D, Berical A, Villacorta-Martin C, Vedaie M, Jacob A, Abo K, Szymaniak A, Peasley M, Stuffer A, Mahoney J, Kotton DN, Hawkins F, Mostoslavsky G. Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells. Nat Commun. 2020;11:215. [PMID: 31924806 DOI: 10.1038/s41467-019-13916-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 21.0] [Reference Citation Analysis]
153 Joshi D, Ehrhardt A, Hong JS, Sorscher EJ. Cystic fibrosis precision therapeutics: Emerging considerations. Pediatr Pulmonol 2019;54 Suppl 3:S13-7. [PMID: 31715091 DOI: 10.1002/ppul.24547] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
154 Raywood E, Douglas H, Kapoor K, Filipow N, Murray N, O'Connor R, Stott L, Saul G, Kuzhagaliyev T, Davies G, Liakhovich O, Van Schaik T, Furtuna B, Booth J, Shannon H, Bryon M, Main E. Protocol for Project Fizzyo, an analytic longitudinal observational cohort study of physiotherapy for children and young people with cystic fibrosis, with interrupted time-series design. BMJ Open 2020;10:e039587. [PMID: 33033031 DOI: 10.1136/bmjopen-2020-039587] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
155 Barry PJ, Taylor-Cousar JL. Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world - opportunities and challenges. Curr Opin Pulm Med 2021;27:554-66. [PMID: 34420018 DOI: 10.1097/MCP.0000000000000819] [Reference Citation Analysis]
156 Viotti Perisse I, Fan Z, Van Wettere A, Liu Y, Leir SH, Keim J, Regouski M, Wilson MD, Cholewa KM, Mansbach SN, Kelley TJ, Wang Z, Harris A, White KL, Polejaeva IA. Sheep models of F508del and G542X cystic fibrosis mutations show cellular responses to human therapeutics. FASEB Bioadv 2021;3:841-54. [PMID: 34632318 DOI: 10.1096/fba.2021-00043] [Reference Citation Analysis]
157 Venturini A, Borrelli A, Musante I, Scudieri P, Capurro V, Renda M, Pedemonte N, Galietta LJV. Comprehensive Analysis of Combinatorial Pharmacological Treatments to Correct Nonsense Mutations in the CFTR Gene. Int J Mol Sci 2021;22:11972. [PMID: 34769402 DOI: 10.3390/ijms222111972] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
158 Fiorotto R, Strazzabosco M. Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota. Cell Mol Gastroenterol Hepatol 2019;8:197-207. [PMID: 31075352 DOI: 10.1016/j.jcmgh.2019.04.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
159 Taylor-Cousar JL, Mall MA, Ramsey BW, McKone EF, Tullis E, Marigowda G, McKee CM, Waltz D, Moskowitz SM, Savage J, Xuan F, Rowe SM. Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles. ERJ Open Res 2019;5:00082-2019. [PMID: 31218221 DOI: 10.1183/23120541.00082-2019] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 10.7] [Reference Citation Analysis]
160 Dagenais RVE, Su VCH, Quon BS. Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review. J Clin Med 2020;10:E23. [PMID: 33374882 DOI: 10.3390/jcm10010023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]